Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorFernández Montes, Ana
dc.contributor.authorAlcaide, Julia
dc.contributor.authorAlsina Maqueda, Maria
dc.contributor.authorCustodio, Ana
dc.contributor.authorFernández Franco, Lourdes
dc.contributor.authorGallego Plazas, Javier
dc.date.accessioned2022-08-12T06:31:17Z
dc.date.available2022-08-12T06:31:17Z
dc.date.issued2022-04
dc.identifier.citationFernández-Montes A, Alcaide J, Alsina M, Belén Custodio A, Fernández Franco L, Gallego Plazas J, et al. SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021). Clin Transl Oncol. 2022 Apr;24:658–69.
dc.identifier.issn1699-3055
dc.identifier.urihttp://hdl.handle.net/11351/7993
dc.descriptionDiagnosis; Esophageal cancer; Treatment
dc.description.abstractEsophageal cancer is an aggressive tumor, and is the sixth-leading cause of death from cancer. Incidence is rising in Spain, particularly among men. Two main pathological different subtypes have been described: squamous cell carcinoma and adenocarcinoma. Growing evidence of their epidemiology and molecular differences explains their different response to novel treatments, and they are therefore likely to be treated as two separate entities in the near future. The best results are obtained with a multidisciplinary therapeutic strategy, and the introduction of immunotherapy is a promising new approach that will improve prognosis. In these guidelines, we review the evidence for the different methods of diagnosis and therapeutic strategies that form the basis of our standard of care.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesClinical and Translational Oncology;24
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectEsòfag - Càncer - Tractament
dc.subjectImmunoteràpia
dc.subjectEsòfag - Càncer - Diagnòstic
dc.subject.meshEsophageal Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshImmunotherapy
dc.titleSEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021)
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s12094-022-02801-2
dc.subject.decsneoplasias del esófago
dc.subject.decs/farmacoterapia
dc.subject.decsinmunoterapia
dc.relation.publishversionhttps://doi.org/10.1007/s12094-022-02801-2
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Fernández-Montes A] Medical Oncology Department, Complexo Hospitalario Universitario de Ourense, Ourense, Spain. [Alcaide J] Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain. [Alsina M] Medical Oncology Department, Hospital Universitario de Navarra (HUN), Pamplona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Custodio AB] Medical Oncology Department, Hospital Universitario la Paz, CIBERONC Madrid, Spain. [Franco LF] Medical Oncology Department, Hospital Virgen de la Salud, Toledo, Spain. [Gallego Plazas J] Medical Oncology Department, Hospital General Universitario de Elche, Elche, Alicante, Spain
dc.identifier.pmid35347573
dc.identifier.wos000773969100002
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record